Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Joshua Kazam
Age : 44
Public asset : 6,594,880 USD
Country of residence : Unknown
Linked companies : Allogene Therapeutics, Inc. - Kronos Bio, Inc. - Tishman Speyer Innovation Corp. II

Biography of Joshua Kazam 
Mr. Joshua A. Kazam is an Independent Director at Soaring Eagle Acquisition Corp., an Independent Director at Tishman Speyer Innovation Corp. II, an Independent Director at TS Innovation Acquisitions Corp., a Director & Partner at Vida Ventures LLC, a Partner at Two River Consulting LLC, a Director & Co-Owner at Riverbank Capital Securities, Inc., a Co-Founder & Partner at Two River Group Holdings LLC, a Co-Founder at VV Manager LLC, a Director & Vice President at Two River Group Management LLC, a Member-Executive Board at The Wharton School of the University of Pennsylvania and a Principal at BCIF Pty Ltd. He is on the Board of Directors at Soaring Eagle Acquisition Corp., Tishman Speyer Innovation Corp. II, TS Innovation Acquisitions Corp., Breakthrough Properties LLC, Breakthrough Services LLC, Allogene Therapeutics, Inc., Vida Ventures LLC, Kronos Bio, Inc., ByHeart, Inc., Desert Flower Foundation GmbH, Vision Path, Inc., MedPod, Inc., Veterinary Prime, Inc., Riverbank Capital Securities, Inc., 105 W First Street LLC, Cortiva Therapy, Danube Pharmaceuticals, Inc., Kirax Corp., Tranzutary Holdings LLC, Vetprime, Inc. and Two River Group Management LLC. Mr. Kazam was previously employed as an Independent Director by Flying Eagle Acquisition Corp., an Independent Director by Diamond Eagle Acquisition Corp., an Independent Director by Platinum Eagle Acquisition Corp., an Independent Director by Capricor Therapeutics, Inc., a Director-Investment Management by Orion Biomedical Fund LP, a Managing Director by Paramount BioCapital, Inc., and a Chief Executive Officer & Director by IconOVir Bio, Inc. He also served on the board at Kite Pharma, Inc., Velcera, Inc., Arno Therapeutics, Inc., Nile Therapeutics, Inc. /Old/, Arno Therapeutics, Inc. /Old/, Manhattan Pharmaceuticals, Inc. and Velcera Pharmaceuticals, Inc. /Old/. He received his undergraduate degree from The Wharton School of the University of Pennsylvania.


Current positions of Joshua Kazam 
Holdings of Joshua Kazam 
Joshua Kazam : Personal Network 
Most Read News 
09/22WILLIAM ACKMAN : Ackman's Pershing Square fund surges as Universal soars in stock debut
RE
09/14BRAD SMITH : Microsoft to buy back up to $60 billion in shares; names Brad Smith vice chair
RE
09/24CATHIE WOOD : Chinese crackdown on bitcoin another blow to Cathie Wood's ARK ETF
RE
09/14CATHIE WOOD : ARK Invest's Wood expects market rotation back to growth stocks
RE
09/13MARTIN SORRELL : Sorrell's S4 Capital raises annual profit outlook for a third time
RE
09/22CATHIE WOOD : ARK's Cathie Wood says Wall Street not in a bubble
RE
09/24ELON MUSK : New semiconductor plants will end global auto chip shortage next year -Tesla's Musk
RE
09/21JEFF BEZOS : UK's Johnson discussed taxation with Amazon's Bezos
RE
09/17STELIOS HAJI-IOANNOU : EasyJet shareholder Stelios Haji-Ioannou shuns rights issue -source
RE
09/24BARRY DILLER : Stock Futures Weaken After Evergrande Payment Deadline Passes
DJ
More news


© 2021 People and Ownership :   
Joshua Kazam : Connections 


Latest news about Joshua Kazam 
02/26Soaring Eagle Acquisition Corp. Announces Board and Committee Appointments
CI
02/17Tishman Speyer Innovation Corp. II Announces Board and Committee Changes
CI
2020TS Innovation Acquisitions Corp. Announces Board Appointments
CI
2020Flying Eagle Acquisition Corp. Announces Board Changes; Adopts Second Amended and Restated Certificate of Incorporation
CI
2019Diamond Eagle Acquisition Corp. Announces Executive Changes
CI
2018Allogene Therapeutics, Inc. Announces Board of Directors
CI
More news